Can Bile Salt Export Pump Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk? An International Transporter Consortium Perspective
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Bile salt export pump (BSEP) inhibition has emerged as an important mechanism that may contribute to the initiation of human drug‐induced liver injury (DILI). Proactive evaluation and understanding of BSEP inhibition is recommended in drug discovery and development to aid internal decision making on DILI risk. BSEP inhibition can be quantified using in vitro assays. When interpreting assay data, it is important to consider in vivo drug exposure. Currently, this can be undertaken most effectively by consideration of total plasma steady state drug concentrations (C ss,plasma). However, because total drug concentrations are not predictive of pharmacological effect, the relationship between total exposure and BSEP inhibition is not causal. Various follow‐up studies can aid interpretation of in vitro BSEP inhibition data and may be undertaken on a case‐by‐case basis. BSEP inhibition is one of several mechanisms by which drugs may cause DILI, therefore, it should be considered alongside other mechanisms when evaluating possible DILI risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ribociclib as first-line therapy for HR-positive, advanced breast cancer
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., André, F., Winer, E. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609709 · Cited by 2,039 · cited 2×
“For example, the oncology drug ribociclib inhibited BSEP activity in vitro, and formed reactive metabolites that could be trapped using reduced glutathione and that bound covalently to human liver microsomal proteins.(104) Although quantitative comparisons between potencies of these in vitro effects and in vivo drug e…”
BackgroundAn analysis of the attrition of drug candidates from four major pharmaceutical companies
Waring, M. J., Arrowsmith, J., Leach, A. R., Leeson, P. D., Mandrell, S., Owen, R. M., Pairaudeau, G., Pennie, W. D., Pickett, S. D., Wang, J., et al. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4609 · Cited by 1,450
Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280
Criteria of drug-induced liver disorders
(1990) · Journal of Hepatology · doi:10.1016/0168-8278(90)90124-a · Cited by 1,106 · cited 1×
“” However, to a clinician, DILI is divided into “hepatocellular,” “cholestatic,” or “mixed” based on the ratio of serum alanine aminotransferase (indicating hepatocyte death) to serum alkaline phosphatase (reflecting reduced bile flow).(23,24) Because bile acids are toxic to the hepatocytes, inhibition of BSEP may pre…”
BackgroundBile-acid-induced cell injury and protection
Perez, M. J., & Briz, O. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.1677 · Cited by 717
Fattinger, K. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.114667 · Cited by 509
FDA-approved drug labeling for the study of drug-induced liver injury
Chen, M., Vijay, V., Shi, Q., Liu, Z., Fang, H., & Tong, W. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.05.007 · Cited by 406
Daly, A. K., Aithal, G. P., Leathart, J. B. S., Swainsbury, R. A., Dang, T. S., & Day, C. P. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.11.023 · Cited by 348 · cited 1×
“In UK patients with iDILI due to diclofenac, an increased frequency of the MRP2 C24T allelic variant was observed, which was proposed to arise because of MRP2mediated biliary excretion of glucuronide metabolites of the drug.(39) In addition, numerous drugs that caused DILI and inhibited BSEP also inhibited MRP2 activi…”
BackgroundDawson, S., Stahl, S., Paul, N., Barber, J., & Kenna, J. G. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.040758 · Cited by 343
Self-citationMorgan, R. E., van Staden, C. J., Chen, Y., Kalyanaraman, N., Kalanzi, J., Dunn, R. T., Afshari, C. A., & Hamadeh, H. K. (2013) · Toxicological Sciences · doi:10.1093/toxsci/kft176 · Cited by 243 · cited 8×
“In addition, numerous drugs that caused DILI and inhibited BSEP also inhibited MRP2 activity in hepatocyte(40) and membrane vesicle(18,19) assays, although overall a poor concordance between inhibition of the two transporters by drugs was observed.(18,19) In humans, multidrug resistance protein 3 (MDR3, encoded by ABC…”
BackgroundMethodInfluentialAleo, M. D., Luo, Y., Swiss, R., Bonin, P. D., Potter, D. M., & Will, Y. (2014) · Hepatology · doi:10.1002/hep.27206 · Cited by 215
Hepatic 3D spheroid models for the detection and study of compounds with cholestatic liability
Hendriks, D. F. G., Fredriksson Puigvert, L., Messner, S., Mortiz, W., & Ingelman-Sundberg, M. (2016) · Scientific Reports · doi:10.1038/srep35434 · Cited by 156
Microfluidic devices for in vitro studies on liver drug metabolism and toxicity
van Midwoud, P. M., Verpoorte, E., & Groothuis, G. M. M. (2011) · Integrative Biology · doi:10.1039/c0ib00119h · Cited by 115
Shoda, L. K. M., Woodhead, J. L., Siler, S. Q., Watkins, P. B., & Howell, B. A. (2014) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1878 · Cited by 75
Self-citationSlizgi, J. R., Lu, Y., Brouwer, K. R., St. Claire, R. L., Freeman, K. M., Pan, M., Brock, W. J., & Brouwer, K. L. R. (2016) · Toxicological Sciences · doi:10.1093/toxsci/kfv231 · Cited by 53
Self-citationKenna, J. G., Stahl, S. H., Eakins, J. A., Foster, A. J., Andersson, L. C., Bergare, J., Billger, M., Elebring, M., Elmore, C. S., & Thompson, R. A. (2015) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.220491 · Cited by 48 · cited 4×
“1, this denotes low DILI concern.(18,19,27) Note that in this calculation, there is no correction for tissue accumulation (e.”
BackgroundInfluentialSelf-citation
Cited by
Andrade, R. J., Chalasani, N., Björnsson, E. S., Suzuki, A., Kullak-Ublick, G. A., Watkins, P. B., Devarbhavi, H., Merz, M., Lucena, M. I., Kaplowitz, N., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0105-0 · Cited by 924
Self-citationDrug induced liver injury: an update
Garcia-Cortes, M., Robles-Diaz, M., Stephens, C., Ortega-Alonso, A., Lucena, M. I., & Andrade, R. J. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02885-1 · Cited by 286
Baudy, A. R., Otieno, M. A., Hewitt, P., Gan, J., Roth, A., Keller, D., Sura, R., Van Vleet, T. R., & Proctor, W. R. (2020) · Lab on a Chip · doi:10.1039/c9lc00768g · Cited by 150
Predicting Drug-Induced Liver Injury with Bayesian Machine Learning
Williams, D. P., Lazic, S. E., Foster, A. J., Semenova, E., & Morgan, P. (2020) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00264 · Cited by 124
Cheng, P. T. W., Kaltenbach, R. F., Zhang, H., Shi, J., Tao, S., Li, J., Kennedy, L. J., Walker, S. J., Shi, Y., Wang, Y., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01256 · Cited by 61
Metadata
- Authors
- Kenna, J. G., Taskar, K. S., Battista, C., Bourdet, D. L., Brouwer, K. L. R., Brouwer, K. R., Dai, D., Funk, C., Hafey, M. J., Lai, Y., Maher, J., Pak, Y. A., Pedersen, J. M., Polli, J. W., Rodrigues, A. D., Watkins, P. B., Yang, K., Yucha, R. W., & On behalf of the International Transporter Consortium
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2018-10-22
- Volume
- 104
- Issue
- 5
- Pages
- 916-932
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2888376928
- Cited by
- 123
- References
- 16
- FWCI
- 3.79
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.